Literature DB >> 7547639

Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas.

E P Henske1, H P Neumann, B W Scheithauer, E W Herbst, M P Short, D J Kwiatkowski.   

Abstract

Angiomyolipomas (AMLs) are renal tumors that occur both sporadically and in association with tuberous sclerosis (TSC). TSC is an autosomal dominant disorder characterized by hamartomatous lesions in multiple organs. Two TSC loci are recognized: TSC1 on 9q34 and TSC2 on 16p13. Loss of heterozygosity (LOH) at the TSC1 and TSC2 loci in lesions from TSC patients has recently been reported. Lesions that are not associated with TSC have not been previously examined for LOH at the TSC loci. We analyzed 29 renal angiomyolipomas from patients without a history of TSC. Three tumors demonstrated LOH on 16p13. This is the first report indicating that mutations in TSC2 occur in tumors of patients who do not have TSC. We also found LOH on 16p13 in 5 of 8 TSC-associated AMLs. Two of these tumors were from a single patient and demonstrated different regions of LOH. These findings support the hypothesis that the TSC2 gene functions as a tumor suppressor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547639     DOI: 10.1002/gcc.2870130411

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  65 in total

1.  Complete inactivation of the TSC2 gene leads to formation of hamartomas.

Authors:  K S Au; A A Hebert; E S Roach; H Northrup
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  Hepatic angiomyolipoma-misdiagnosis as hepatocellular carcinoma: A report of 14 cases.

Authors:  Ding-Rong Zhong; Xiao-Long Ji
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 3.  Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms.

Authors:  S Johnson
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

4.  Identification of a leader exon and a core promoter for the rat tuberous sclerosis 2 (Tsc2) gene and structural comparison with the human homolog.

Authors:  T Kobayashi; S Urakami; J P Cheadle; R Aspinwall; P Harris; J R Sampson; O Hino
Journal:  Mamm Genome       Date:  1997-08       Impact factor: 2.957

5.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

Authors:  T Carsillo; A Astrinidis; E P Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

6.  Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2.

Authors:  T Soucek; R S Yeung; M Hengstschläger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

7.  Tuberous sclerosis complex 2 loss of heterozygosity in patients with lung disease and cancer.

Authors:  Li Zhang; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Jiro Kato; Mary Haughey; Joseph R Fontana; Vincent C Manganiello; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

Review 8.  Perivascular epithelioid tumours (PEComas) of the gynaecological tract.

Authors:  Niamh Conlon; Robert A Soslow; Rajmohan Murali
Journal:  J Clin Pathol       Date:  2015-03-06       Impact factor: 3.411

Review 9.  New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex.

Authors:  Hilaire C Lam; Julie Nijmeh; Elizabeth P Henske
Journal:  J Pathol       Date:  2016-11-29       Impact factor: 7.996

10.  The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Authors:  T R Hartman; E Nicolas; A Klein-Szanto; T Al-Saleem; T P Cash; M C Simon; E P Henske
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.